Clinical trials: Diabetes Type 2
Type II Diabetes
Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling
In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification…
- Trial name
- NCT02637609
- Testing
- Likert Scale, Best-Worst Scaling (Case 1)
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Type 2 Diabetes Mellitus
The LoBAG Diet and Type 2 Diabetes Mellitus
The proposed study is a randomized controlled, pilot effectiveness trial comparing the LoBAG diet to a control diet in 38 participants with DM2 over 12 weeks.
- Trial name
- NCT02717078
- Testing
- Diet Therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Minnesota
Type 2 Diabetes, Impaired Renal Function
Linagliptin's Effect on CD34+ Stem Cells
Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels which may contribute to heart disease. Endothelial Progenitor Cells (EPCs) are found in the blood.
- Trial name
- NCT02467478
- Testing
- Linagliptin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Washington University
Type 2 Diabetes
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
- Trial name
- NCT00817778
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
The purpose of this study is to evaluate the efficacy and safety of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are…
- Trial name
- NCT02354235
- Testing
- Teneligliptin, Canagliflozin
- Where
- 3 sites in Japan
- Volunteers
- 138 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Type 2 Diabetes, Diabetes
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers.
- Trial name
- NCT00339833
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin…
- Trial name
- NCT00954447
- Testing
- Linagliptin
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,263 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
Renoprotection in Early Diabetic Nephropathy in Pima Indians
This investigation is a randomized, double-blinded, placebo-controlled clinical trial in adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine ration less than 30 mg/g) or microalbuminuria…
- Trial name
- NCT00340678
- Testing
- Losartan
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318109
- Testing
- Alogliptin and metformin, Metformin
- Volunteers
- 288 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02318693
- Testing
- Sitagliptin, Glibenclamide
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus
The purpose of this study is to investigate the safety and efficacy of long-term use of pioglitazone/metformin hydrochloride combination tablets in the routine clinical setting in patients with type 2 diabetes mellitus for whom…
- Trial name
- NCT02024971
- Testing
- Pioglitazone/metformin hydrochloride
- Volunteers
- 1,103 people
- Sponsor
- Takeda
Heart Diseases, Diabetes Mellitus, Type 2
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
- Conditions
- Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension
- Trial name
- CV-Homes (NCT06025721)
- Testing
- Cardiovascular Risk Homeless Support
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Katherine Vickery
Type 2 Diabetes Mellitus
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with…
- Trial name
- NCT02924064
- Testing
- Teneligliptin 20mg, Metformin ≥ 1000 mg
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
The purpose of this study was to investigate the effect of a high-fat meal on the levels of bexagliflozin in the blood in healthy subjects.
- Trial name
- NCT02820298
- Testing
- Bexagliflozin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theracos
Obesity, Gliosis, Weight-Loss
A Cohort Study of Weight Loss and Gliosis
Patients and clinicians need better options to prevent the weight regain that almost universally follows a weight loss intervention. In lay terms, a new, higher "set point" seems to occur after people gain weight.
- Trial name
- NCT03578887
- Testing
- Behavioral Weight Loss Program, Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Washington